---

As therapeutic options develop for the tre-atment of multiple sclerosis (MS), there is an increasing necessity to find biomarkers with high sensitivity and being useful to detect the activity and disease course. Such biomarkers with high selectivity and accuracy can be used to evaluate therap-eutic responsiveness, early diagnosis, and early treatment and to show the stage of the disease. For instance, presence of oligocl-onal bands within CSF of MS-CIS, anti-aquaporin 4 for differentiation of MS disease from Neuromyelitis Optica, prese-nce of neutralizing antibodies against inter-feron-beta in serum samples of MS patients to assess responders vs. nonresponders, are the benefits of biomarkers in disease study. Despite the above advantages, there is no given biomarker to definitely diagnosis the MS disease. The emergence of advanced molecular techniques opened a new horizon to find more sensitive and selective biom-arkers to diagnosis the disease at early stages